Johnson & Johnson Reports 2021 First-Quarter Results:

Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) reported strong first-quarter 2021 results, with reported sales reaching $22.32 billion, representing a 7.9% increase from $20.69 billion in 2020. Net earnings rose to $6.20 billion, up 6.9% year-over-year, resulting in an EPS of $2.32. The Pharmaceutical segment led growth with a 9.6% increase, driven by key products like DARZALEX and STELARA. Medical Devices also saw an 8.8% growth, aided by recovery from COVID impacts. However, Consumer Health segment sales declined 2.3% due to prior year comparisons.

Positive

• Reported sales increased 7.9% to $22.32 billion.
• Strong net earnings growth of 6.9%, totaling $6.20 billion.
• Pharmaceutical sales increased 9.6%, driven by successful products like DARZALEX.
• Medical Devices segment grew 8.8%, reflecting market recovery.

Negative

• Consumer Health segment sales declined 2.3%, affected by COVID-related pantry loading in Q1 2020.

NEW BRUNSWICK, N.J., April 20, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. "Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices," said Alex Gorsky, Chairman and Chief Executive Officer. "The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000 employees of Johnson & Johnson who strive every day to profoundly change the trajectory of health for humanity and make healthier communities for everyone, everywhere."

OVERALL FINANCIAL RESULTS: 

	FIRST QUARTER
($ in Millions, except EPS)	2021	2020	%  Change
Reported Sales	$        22,321	$        20,691	7.9%
Net Earnings	6,197	5,796	6.9
EPS (diluted)	$            2.32	$            2.17	6.9%
Non-GAAP*	FIRST QUARTER
($ in Millions, except EPS)	2021	2020	%  Change
Operational Sales1,2			5.5%
Adjusted Operational Sales1,3			6.0
Adjusted Net Earnings1,4	6,924	6,154	12.5
Adjusted EPS (diluted)1,4	$            2.59	$            2.30	12.6%

1	Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2	Excludes the impact of translational currency
3	Excludes the net impact of acquisitions and divestitures and translational currency
4	Excludes intangible amortization expense and special items

REGIONAL SALES RESULTS: 

	FIRST QUARTER		%  Change
($ in Millions)	2021	2020	Reported	Operational1,2	Currency	Adjusted Operational1,3
U.S.	$        11,111	$        10,699	3.9%	3.9	-	3.9
International	11,210	9,992	12.2	7.3	4.9	8.2
Worldwide	$        22,321	$        20,691	7.9%	5.5	2.4	6.0

1	Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2	Excludes the impact of translational currency
3	Excludes the net impact of acquisitions and divestitures and translational currency
	Note: values may have been rounded

SEGMENT SALES RESULTS:

	FIRST QUARTER		%  Change
($ in Millions)	2021	2020	Reported	Operational1,2	Currency	Adjusted Operational1,3
Consumer Health	$          3,543	$          3,625	(2.3)%	(3.3)	1.0	(2.9)
Pharmaceutical	12,199	11,134	9.6	7.1	2.5	7.4
Medical Devices	6,579	5,932	10.9	8.0	2.9	8.8
Worldwide	$        22,321	$        20,691	7.9%	5.5	2.4	6.0

1	Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2	Excludes the impact of translational currency
3	Excludes the net impact of acquisitions and divestitures and translational currency
	Note: values may have been rounded

FIRST-QUARTER 2021 SEGMENT COMMENTARY:

Consumer Health
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products.  Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON'S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.

Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,  INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, and U.S. ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.

Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.

NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:  
The information contained in this section should be read in conjunction with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases available online in the Investors section of the company's website at news releases.

Regulatory Decisions	PONVORY (ponesimod) approved by U.S. FDA, an oral treatment for adults with relapsing multiple sclerosis proven superior to (teriflunomide) in reducing annual relapses and brain lesions	(press release)
	Johnson & Johnson Single-Shot COVID-19 Vaccine granted conditional marketing authorization by European Commission	(press release)
	Johnson & Johnson Single-Shot COVID-19 Vaccine granted emergency use listing by the World Health Organization	(press release)
	Johnson & Johnson COVID-19 Vaccine authorized by U.S. FDA for emergency use	(press release)
	SPRAVATO (Esketamine Nasal Spray) authorized in Europe for the rapid reduction of depressive symptoms in a psychiatric emergency for patients with major depressive disorder	(press release)
	MONOFOCAL INTRAOCULAR LENS - TECNIS EYHANCE AND TECNIS EYHANCE TORIC II IOLS - receives FDA approval for a next generation treatment for cataract patients	(press release)
Regulatory Submission	Submission of supplemental new drug application to U.S. FDA by ViiV Healthcare for expanded use of CABENUVA (rilpivirine and cabotegravir) as an HIV treatment for use every two months	(press release)
Other	Janssen provides update on Phase 3 ACIS Study in patients with metastatic castration- resistant prostate cancer treated with ERLEADA (apalutamide) and ZYTIGA (abiraterone acetate) plus prednisone combination ¹	(press release)
	Johnson & Johnson announces advance purchase agreement with the African Vaccine Acquisition Trust for the Company's COVID-19 vaccine candidate	(press release)
	PONVORY (ponesimod) receives positive CHMP opinion for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features	(press release)
	CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) accepted for accelerated assessment in Europe for the treatment of patients with heavily pretreated multiple myeloma	(press release)

1 Subsequent to the quarter

FULL-YEAR 2021 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

($ in Billions, except EPS)	January 2021	April 2021
Adjusted Operational Sales1,2 Change vs. Prior Year	8.0% - 9.5%	8.7% - 9.9%
Operational Sales2 Change vs. Prior Year	$88.8B - $90.0B 7.5% – 9.0%	$89.3B - $90.3B 8.2% – 9.4%
Estimated Reported Sales3 Change vs. Prior Year	$90.5B - $91.7B  9.5% – 11.0%	$90.6B - $91.6B 9.7% – 10.9%
Adjusted Operational EPS (Diluted)2,4 Change vs. Prior Year	$9.25 - $9.45 15.2% - 17.7%	$9.30 - $9.45 15.8% - 17.7%
Adjusted EPS (Diluted)3,4 Change vs. Prior Year	$9.40 - $9.60 17.1% - 19.6%	$9.42 - $9.57 17.3% - 19.2%

1	Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2	Non-GAAP financial measure; excludes the impact of translational currency
3	Calculated using Euro Average Rate: January 2021 = $1.21 and April 2021 = $1.19 (Illustrative purposes only)
4	Non-GAAP financial measure; excludes intangible amortization expense and special items

Other modeling considerations will be provided on the webcast.

WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the company's website at events-and-presentations. 

ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. 

NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the company's website at quarterly-results.

Copies of the financial schedules accompanying this earnings release are available on the company's website at quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can also be found in the Investors section of the company's website at quarterly-results.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021 including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," in the Company's most recently filed Quarterly Report on Form 10-Q and the Company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)		FIRST QUARTER
						Percent Change
		2021		2020		Total		Operations		Currency
Sales to customers by
segment of business
Consumer Health
U.S.		$     1,611		1,740		(7.4)	%	(7.4)		-
International		1,932		1,885		2.5		0.5		2.0
		3,543		3,625		(2.3)		(3.3)		1.0
Pharmaceutical
U.S.		6,446		6,061		6.4		6.4		-
International		5,753		5,073		13.4		7.9		5.5
		12,199		11,134		9.6		7.1		2.5
Medical Devices
U.S.		3,054		2,898		5.4		5.4		-
International		3,525		3,034		16.2		10.5		5.7
		6,579		5,932		10.9		8.0		2.9
U.S.		11,111		10,699		3.9		3.9		-
International		11,210		9,992		12.2		7.3		4.9
Worldwide		$   22,321		20,691		7.9	%	5.5		2.4
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

 

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)	FIRST QUARTER
					Percent Change
	2021		2020		Total		Operations		Currency
Sales to customers by
geographic area
U.S.	$    11,111		10,699		3.9	%	3.9		-
Europe	5,414		4,827		12.1		4.7		7.4
Western Hemisphere excluding U.S.	1,424		1,502		(5.1)		0.0		(5.1)
Asia-Pacific, Africa	4,372		3,663		19.4		13.7		5.7
International	11,210		9,992		12.2		7.3		4.9
Worldwide	$    22,321		20,691		7.9	%	5.5		2.4
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

 

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)	FIRST QUARTER
	2021				2020				Percent
			Percent				Percent		Increase
	Amount		to Sales		Amount		to Sales		(Decrease)
Sales to customers	$      22,321		100.0		$      20,691		100.0		7.9
Cost of products sold	7,063		31.7		7,062		34.1		0.0
Gross Profit	15,258		68.3		13,629		65.9		12.0
Selling, marketing and administrative expenses	5,432		24.3		5,203		25.1		4.4
Research and development expense	3,178		14.2		2,580		12.5		23.2
Interest (income) expense, net	48		0.2		(42)		(0.2)
Other (income) expense, net	(882)		(3.9)		(679)		(3.3)
Restructuring	53		0.2		58		0.3
Earnings before provision for taxes on income	7,429		33.3		6,509		31.5		14.1
Provision for taxes on income	1,232		5.5		713		3.5		72.8
Net earnings	6,197		27.8		5,796		28.0		6.9
Net earnings per share (Diluted)	$          2.32				$          2.17				6.9
Average shares outstanding (Diluted)	2,672.7				2,671.0
Effective tax rate	16.6	%			11.0	%
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income	$        8,291		37.1		$        7,244		35.0		14.5
Net earnings	$        6,924		31.0		$        6,154		29.7		12.5
Net earnings per share (Diluted)	$          2.59				$          2.30				12.6
Effective tax rate	16.5	%			15.0	%
(1) See Reconciliation of Non-GAAP Financial Measures.

 

 

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
			First Quarter
	(Dollars in Millions Except Per Share Data)		2021		2020
	Net Earnings, after tax- as reported		$6,197		$5,796
	Pre-tax Adjustments
	Intangible Asset Amortization expense		1,215		1,118
	Litigation expense		-		120
	Restructuring related		104		118
	Acquisition, integration and divestiture related 1		(538)		(962)
	Unrealized (gains)/losses on securities		35		327
	Medical Device Regulation		46		14
	Tax Adjustments
	Tax impact on special item adjustments2		(113)		(267)
	Tax legislation and other tax related		(22)		(110)
	Adjusted Net Earnings, after tax		$6,924		$6,154
	Average shares outstanding (Diluted)		2,672.7		2,671.0
	Adjusted net earnings per share (Diluted)		$2.59		$2.30
	Operational adjusted net earnings per share (Diluted)		$2.49
	Notes:
1	Acquisition, integration and divestiture related for the first quarter of 2021 primarily includes the gain on the divestiture of 2 Pharmaeutical brands outside of the U.S.  The first quarter of 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.
2	The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

 

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth
FIRST QUARTER 2021 ACTUAL vs. 2020 ACTUAL
Segments
		Consumer Health		Pharmaceutical		Medical Devices		Total
WW As Reported		(2.3)%		9.6%		10.9%		7.9%
U.S.		(7.4)%		6.4%		5.4%		3.9%
International		2.5%		13.4%		16.2%		12.2%
WW Currency		1.0		2.5		2.9		2.4
U.S.		-		-		-		-
International		2.0		5.5		5.7		4.9
WW Operational		(3.3)%		7.1%		8.0%		5.5%
U.S.		(7.4)%		6.4%		5.4%		3.9%
International		0.5%		7.9%		10.5%		7.3%
General Surgery
Advanced Sterilization Products						0.6		0.2
U.S.						0.0		0.0
International						1.2		0.4
All Other Acquisitions and Divestitures		0.4		0.3		0.1		0.3
U.S.		0.5		(0.2)		0.2		0.0
International		0.4		0.9		0.0		0.5
WW Adjusted Operational		(2.9)%		7.4%		8.8%		6.0%
U.S.		(6.9)%		6.2%		5.6%		3.9%
International		0.9%		8.8%		11.8%		8.2%
Note: Percentages are based on actual, non-rounded figures and may not sum

 

		REPORTED SALES vs. PRIOR PERIOD ($MM)
	FIRST QUARTER
					% Change
		2021		2020	Reported	Operational (1)	Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US		$              599		689	-13.0%	-13.0%	-
Intl		575		659	-12.8%	-16.6%	3.8%
WW		1,175		1,348	-12.9%	-14.8%	1.9%
SKIN HEALTH / BEAUTY
US		634		659	-3.9%	-3.9%	-
Intl		529		458	15.7%	12.3%	3.4%
WW		1,163		1,117	4.1%	2.8%	1.3%
ORAL CARE
US		163		176	-7.2%	-7.2%	-
Intl		254		219	16.0%	13.9%	2.1%
WW		417		395	5.7%	4.5%	1.2%
BABY CARE
US		96		92	4.2%	4.2%	-
Intl		293		269	8.9%	11.3%	-2.4%
WW		389		361	7.7%	9.5%	-1.8%
WOMEN'S HEALTH
US		3		4	-25.8%	-25.8%	-
Intl		219		228	-3.9%	-2.2%	-1.7%
WW		222		232	-4.3%	-2.6%	-1.7%
WOUND CARE / OTHER
US		115		119	-3.0%	-3.0%	-
Intl		61		52	17.6%	14.2%	3.4%
WW		177		171	3.3%	2.2%	1.1%
TOTAL CONSUMER HEALTH
US		1,611		1,740	-7.4%	-7.4%	-
Intl		1,932		1,885	2.5%	0.5%	2.0%
WW		$           3,543		3,625	-2.3%	-3.3%	1.0%
See footnotes at end of schedule
		REPORTED SALES vs. PRIOR PERIOD ($MM)
	FIRST QUARTER
					% Change
PHARMACEUTICAL SEGMENT (2,3)		2021		2020	Reported	Operational (1)	Currency
IMMUNOLOGY
US		$           2,413		2,410	0.1%	0.1%	-
Intl		1,501		1,228	22.3%	15.9%	6.4%
WW		3,914		3,638	7.6%	5.5%	2.1%
REMICADE
US		489		625	-21.7%	-21.7%	-
US Exports (4)		57		110	-48.4%	-48.4%	-
Intl		232		256	-9.4%	-12.1%	2.7%
WW		777		990	-21.5%	-22.2%	0.7%
SIMPONI / SIMPONI ARIA
US		255		272	-5.9%	-5.9%	-
Intl		307		258	18.9%	13.8%	5.1%
WW		562		529	6.2%	3.7%	2.5%
STELARA
US		1,331		1,217	9.4%	9.4%	-
Intl		817		603	35.6%	27.6%	8.0%
WW		2,148		1,819	18.1%	15.4%	2.7%
TREMFYA
US		274		187	46.3%	46.3%	-
Intl		143		109	32.0%	23.1%	8.9%
WW		418		296	41.0%	37.8%	3.2%
OTHER IMMUNOLOGY
US		7		-	*	*	-
Intl		2		3	-38.4%	-36.3%	-2.1%
WW		8		3	*	*	*
INFECTIOUS DISEASES
US		512		436	17.4%	17.4%	-
Intl		494		483	2.3%	-2.2%	4.5%
WW		1,007		920	9.5%	7.1%	2.4%
COVID-19 VACCINE
US		100		-	*	*	-
Intl		-		-	-	-	-
WW		100		-	*	*	-
EDURANT / rilpivirine
US		10		12	-12.3%	-12.3%	-
Intl		233		212	9.8%	0.9%	8.9%
WW		243		224	8.6%	0.2%	8.4%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US		380		396	-3.8%	-3.8%	-
Intl		166		184	-9.9%	-10.4%	0.5%
WW		546		579	-5.8%	-5.9%	0.1%
OTHER INFECTIOUS DISEASES
US		21		29	-27.0%	-27.0%	-
Intl		96		87	9.7%	7.4%	2.3%
WW		117		116	0.6%	-1.2%	1.8%
		REPORTED SALES vs. PRIOR PERIOD ($MM)
	FIRST QUARTER
					% Change
		2021		2020	Reported	Operational (1)	Currency
NEUROSCIENCE
US		771		748	3.2%	3.2%	-
Intl		949		910	4.3%	0.4%	3.9%
WW		1,721		1,658	3.8%	1.6%	2.2%
CONCERTA / Methylphenidate
US		47		52	-9.6%	-9.6%	-
Intl		123		118	4.5%	-0.4%	4.9%
WW		171		171	0.2%	-3.2%	3.4%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
US		589		544	8.3%	8.3%	-
Intl		376		339	11.0%	4.5%	6.5%
WW		965		883	9.4%	6.9%	2.5%
RISPERDAL CONSTA
US		67		76	-11.8%	-11.8%	-
Intl		89		94	-4.8%	-8.8%	4.0%
WW		157		170	-7.9%	-10.1%	2.2%
OTHER NEUROSCIENCE
US		67		75	-9.8%	-9.8%	-
Intl		361		360	0.2%	-0.9%	1.1%
WW		428		435	-1.5%	-2.5%	1.0%
ONCOLOGY
US		1,377		1,175	17.2%	17.2%	-
Intl		2,193		1,839	19.3%	12.9%	6.4%
WW		3,570		3,013	18.5%	14.6%	3.9%
DARZALEX
US		691		463	49.2%	49.2%	-
Intl		674		474	42.2%	35.3%	6.9%
WW		1,365		937	45.6%	42.2%	3.4%
ERLEADA
US		171		119	44.0%	44.0%	-
Intl		90		24	*	*	*
WW		261		143	82.8%	79.7%	3.1%
IMBRUVICA
US		444		432	2.8%	2.8%	-
Intl		680		599	13.5%	7.6%	5.9%
WW		1,125		1,031	9.0%	5.6%	3.4%
ZYTIGA / abiraterone acetate
US		50		139	-64.2%	-64.2%	-
Intl		588		552	6.6%	0.0%	6.6%
WW		638		690	-7.6%	-12.9%	5.3%
OTHER ONCOLOGY(5)
US		21		22	-5.1%	-5.1%	-
Intl		161		190	-15.3%	-19.3%	4.0%
WW		182		212	-14.2%	-17.9%	3.7%
		REPORTED SALES vs. PRIOR PERIOD ($MM)
	FIRST QUARTER
					% Change
		2021		2020	Reported	Operational (1)	Currency
PULMONARY HYPERTENSION
US		573		486	18.0%	18.0%	-
Intl		288		260	10.8%	5.6%	5.2%
WW		861		745	15.5%	13.7%	1.8%
OPSUMIT
US		272		229	18.5%	18.5%	-
Intl		179		160	11.5%	6.3%	5.2%
WW		450		389	15.6%	13.5%	2.1%
UPTRAVI
US		259		212	21.9%	21.9%	-
Intl		46		38	23.0%	15.7%	7.3%
WW		305		250	22.0%	20.9%	1.1%
OTHER PULMONARY HYPERTENSION
US		42		44	-3.5%	-3.5%	-
Intl		63		62	1.4%	-2.1%	3.5%
WW		105		106	-0.6%	-2.7%	2.1%
CARDIOVASCULAR / METABOLISM / OTHER
US		799		806	-0.9%	-0.9%	-
Intl		328		354	-7.2%	-11.3%	4.1%
WW		1,127		1,160	-2.8%	-4.1%	1.3%
XARELTO
US		589		527	11.7%	11.7%	-
Intl		-		-	-	-	-
WW		589		527	11.7%	11.7%	-
INVOKANA / INVOKAMET
US		87		117	-26.1%	-26.1%	-
Intl		63		58	9.2%	4.2%	5.0%
WW		150		175	-14.4%	-16.1%	1.7%
PROCRIT / EPREX
US		62		76	-18.3%	-18.3%	-
Intl		64		79	-18.1%	-22.2%	4.1%
WW		127		155	-18.2%	-20.3%	2.1%
OTHER
US		60		85	-28.8%	-28.8%	-
Intl		201		217	-7.7%	-11.5%	3.8%
WW		261		302	-13.6%	-16.4%	2.8%
TOTAL PHARMACEUTICAL
US		6,446		6,061	6.4%	6.4%	-
Intl		5,753		5,073	13.4%	7.9%	5.5%
WW		$         12,199		11,134	9.6%	7.1%	2.5%
See footnotes at end of schedule
		REPORTED SALES vs. PRIOR PERIOD ($MM)
	FIRST QUARTER
					% Change
MEDICAL DEVICES SEGMENT (2)		2021		2020	Reported	Operational (1)	Currency
INTERVENTIONAL SOLUTIONS
US		$              434		365	19.0%	19.0%	-
Intl		514		362	42.0%	34.0%	8.0%
WW		949		727	30.4%	26.4%	4.0%
ORTHOPAEDICS
US		1,249		1,250	-0.1%	-0.1%	-
Intl		864		788	9.7%	3.1%	6.6%
WW		2,113		2,038	3.7%	1.2%	2.5%
HIPS
US		210		206	2.4%	2.4%	-
Intl		146		132	11.2%	4.5%	6.7%
WW		357		337	5.8%	3.2%	2.6%
KNEES
US		185		214	-13.5%	-13.5%	-
Intl		132		130	2.0%	-4.1%	6.1%
WW		317		343	-7.6%	-9.9%	2.3%
TRAUMA
US		450		407	10.7%	10.7%	-
Intl		282		247	14.4%	7.7%	6.7%
WW		733		654	12.1%	9.5%	2.6%
SPINE, SPORTS & OTHER
US		403		423	-4.8%	-4.8%	-
Intl		303		280	8.4%	1.7%	6.7%
WW		706		703	0.4%	-2.2%	2.6%
		REPORTED SALES vs. PRIOR PERIOD ($MM)
	FIRST QUARTER
					% Change
		2021		2020	Reported	Operational (1)	Currency
SURGERY
US		898		844	6.5%	6.5%	-
Intl		1,474		1,257	17.3%	11.7%	5.6%
WW		2,372		2,100	12.9%	9.6%	3.3%
ADVANCED
US		405		381	6.5%	6.5%	-
Intl		713		567	25.7%	19.5%	6.2%
WW		1,118		948	18.0%	14.3%	3.7%
GENERAL
US		493		463	6.5%	6.5%	-
Intl		761		690	10.3%	5.3%	5.0%
WW		1,254		1,153	8.8%	5.8%	3.0%
VISION
US		472		439	7.4%	7.4%	-
Intl		673		628	7.3%	3.9%	3.4%
WW		1,145		1,067	7.3%	5.4%	1.9%
CONTACT LENSES / OTHER
US		371		346	7.2%	7.2%	-
Intl		486		467	4.0%	0.9%	3.1%
WW		857		814	5.3%	3.5%	1.8%
SURGICAL
US		101		93	8.2%	8.2%	-
Intl		187		160	17.0%	12.9%	4.1%
WW		288		253	13.7%	11.2%	2.5%
TOTAL MEDICAL DEVICES
US		3,054		2,898	5.4%	5.4%	-
Intl		3,525		3,034	16.2%	10.5%	5.7%
WW		$           6,579		5,932	10.9%	8.0%	2.9%
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,  therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
(5) Refer to supplemental schedule

Supplemental Sales Information
(Dollars in Millions)
Prior quarter amounts have been reclassified to
conform to current quarter product disclosure
		2019				2020									2020
	PHARMACEUTICAL SEGMENT(1)		Full Year				Q1		Q2		Q3		Q4			Full Year
	Oncology
	OTHER ONCOLOGY(2)
	US		70				22		20		21		20			83
	Intl		1,087				190		185		181		183			738
	WW		1,158				212		204		203		202			821
	Note: Columns and rows within tables may not add due to rounding.
	(1) Unaudited
	(2) Other Oncology is inclusive of VELCADE, which was previously disclosed separately

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2021-first-quarter-results-301272130.html

SOURCE Johnson & Johnson